ROKITAMYCIN
ROKITAMYCIN Basic information
- Product Name:
- ROKITAMYCIN
- Synonyms:
-
- 3''-Propionylleucomycin A5
- Leucomycin V, 4B-butanoate 3B-propanoate (9CI)
- Ricamycin
- TMS 19Q
- ROKITAMYCIN
- Leummycin V 4B-bu-tanoate 3 B-propanoate
- M-19-Q
- Rikamycin
- CAS:
- 74014-51-0
- MF:
- C42H69NO15
- MW:
- 827.99
- Mol File:
- 74014-51-0.mol
ROKITAMYCIN Chemical Properties
- Melting point:
- 116°
- alpha
- D20 -71° (c = 1.0 in chloroform)
- Boiling point:
- 879.3±65.0 °C(Predicted)
- Density
- 1.21±0.1 g/cm3(Predicted)
- storage temp.
- Inert atmosphere,Store in freezer, under -20°C
- pka
- 13.06±0.70(Predicted)
- CAS DataBase Reference
- 74014-51-0
ROKITAMYCIN Usage And Synthesis
Description
Rokitamycin is a semisynthetic macrolide antibiotic, closely related to miokamycin(2) both in structure and antimicrobial spectrum.
Originator
Toyo Jozo (Japan)
Definition
ChEBI: Rokitamycin is an organic molecular entity.
brand name
RICAMYCIN
Pharmaceutical Applications
3″-Propionyl leucomycin A5. A semisynthetic macrolide. Unstable in acid media.
The antibacterial spectrum is identical to that of erythromycin, but it is less active against Gram-positive cocci. It is poorly active against H. influenzae (MIC50 8 mg/L) and Mor. catarrhalis (MIC50 4 mg/L). It displays good activity against Campylobacter spp. (MIC50 0.1 mg/L), L. pneumophila (MIC50 0.1 mg/L) and M. pneumoniae (MIC50 0.003 mg/L). It is active against anaerobes, including some Bacteroides spp. (MIC50 <0.05 mg/L).
After a single oral dose of 600 mg, the peak plasma concentration was 1.9 mg/L after 0.6 h. Oral doses of 5, 10 and 15 mg/kg of a syrup formulation given to children achieved plasma concentrations of 0.26, 0.55 and 0.79 mg/L, respectively, after about 40 min. The half-life is around 2 h.
It is mainly eliminated in the bile; only about 2% appears in the urine. Its major metabolites are leucomycin A7, 10″-OH-rokitamycin (which show some antibacterial activity) and leucomycin V. In healthy adult volunteers, the proportions of rokitamycin and its metabolites in serum 30 min after a single oral dose of 1200 mg were 18% (leucomycin A7), 33% (10″-OH-rokitamycin) and 9% (leucomycin V). The pharmacokinetic behavior is not altered in patients with liver cirrhosis. It is available in Italy and Japan.
ROKITAMYCIN Preparation Products And Raw materials
Raw materials
ROKITAMYCINSupplier
- Tel
- 010-56205725
- waley188@sohu.com
- Tel
- 15971444841
- amber@biochempartner.com
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Tel
- +86-029-89586680 +86-18192503167
- 1026@dideu.com
- Tel
- +86-29-87569262 +86-15319487004
- 1015@dideu.com